On March 11, 2010, Robert S. Chilton tendered his resignation as Chief Financial Officer and Director of HemaCare Corporation ("Registrant"), and from all other positions he holds with the Registrant and its subsidiaries, effective March 26, 2010. In connection with his resignation, on March 15, 2010, the Registrant entered into a Separation Agreement, dated March 15, 2010, with Mr. Chilton, wherein in exchange for a release of any employment related claims Mr. Chilton could assert against the Registrant, the Registrant agreed to pay Mr. Chilton $115,000 on April 26, 2010.

On March 11, 2010, the Registrant's Board of Directors appointed Pete van der Wal as the Registrant's Chief Financial Officer, with such appointment to be effective upon the effective date of Mr. Chilton's resignation. Mr. van der Wal currently serves as the Registrant's President and Chief Executive Officer, and as a member of the Board of Directors.

On March 11, 2010, the Registrant entered into an Employment Agreement, dated March 2, 2010, with Pete van der Wal, wherein effective April 1 2010, Mr. van der Wal will receive a base annual salary of $225,000, and is eligible to receive an annual bonus, subject to achieving specified goals as determined by the Registrant's Board of Directors, of up to 67% of his base annual salary, payable by March 15 of the following calendar year. Mr. van der Wal is also entitled to the same benefits as other similarly situated employees.

On March 11, 2010, the Registrant entered into a Separation Agreement, dated February 26, 2010, with John Doumitt, the Registrant's former Chief Executive Officer wherein in exchange for a release of any employment related claims Mr. Doumitt could assert against the Registrant, the Registrant agreed to pay Mr. Doumitt $62,500 on April 9, 2010.

The foregoing summary is qualified in its entirety by reference to the copies of these agreements which are filed as Exhibits 10.1, 10.2, and 10.3 to this report and are incorporated herein by reference.